Medline (MDLN) CPO Amanda Laabs receives RSUs and unit awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Medline Inc. Chief Product Officer Amanda H. Laabs reported equity awards rather than open‑market trades. On March 5, 2026, she acquired 25,788 shares of Class A common stock at $0.00 per share as a grant of restricted stock units. According to the disclosure, 25% of these RSUs vest on June 15, 2026, with the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.

The filing also details prior awards from December 16, 2025, including 251,070 Common Units of Medline Holdings, LP and several tranches of Incentive Units, all acquired at $0.00 per unit. These units are held indirectly through Medline Management Aggregator LLC and can be exchanged into Common Units, which in turn are exchangeable on a one‑for‑one basis for Class A common stock under an exchange agreement. Class B common stock, issued one share for each Common Unit, carries voting rights but no economic value and is cancelled upon exchange into Class A shares.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Laabs Amanda H.

Role Chief Product Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	25,788	$0.00	--
Grant/Award	Common Units of Medline Holdings, LP	251,070	$0.00	--
Grant/Award	Incentive Units of Medline Holdings, LP	1,242,391	$0.00	--
Grant/Award	Incentive Units of Medline Holdings, LP	189,352	$0.00	--
Grant/Award	Incentive Units of Medline Holdings, LP	132,771	$0.00	--
Grant/Award	Incentive Units of Medline Holdings, LP	220,813	$0.00	--
Grant/Award	Class B Common Stock	251,070	$0.00	--

Holdings After Transaction: Class A Common Stock — 25,788 shares (Direct); Common Units of Medline Holdings, LP — 251,070 shares (Indirect, See Footnote); Incentive Units of Medline Holdings, LP — 1,242,391 shares (Indirect, See Footnote); Class B Common Stock — 251,070 shares (Direct)

Footnotes (1)

These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025. Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each common unit of Medline Holdings, LP ("Common Units") held. Upon an exchange of Common Units for shares of the Issuer's Class A common stock ("Class A Common Stock"), an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled. Represents a grant of restricted stock units ("RSUs"), of which 25% vest on June 15, 2026 and the remaining 75% vest in three equal annual installments beginning on March 1, 2027. Pursuant to the terms of an exchange agreement, dated as of December 16, 2025 (the "Exchange Agreement"), holders have the right to exchange their Common Units for shares of the Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units are held indirectly through Medline Management Aggregator LLC. Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments. (Continued from Footnote 5 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC. 80% of these Incentive Units have vested, and the remaining 20% vest on October 21, 2026. 40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on April 1, 2026. 20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on March 29, 2026. These Incentive Units vest in five equal annual installments beginning on March 28, 2026.

Form 4 Insider Transactions: What Each Field Means →

03/06/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laabs Amanda H.

(Last)

(First)

(Middle)

C/O MEDLINE INC.

3 LAKES DRIVE

(Street)

NORTHFIELD

60093

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Medline Inc. [ MDLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Product Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class B Common Stock	12/16/2025		A⁽¹⁾		251,070⁽²⁾	A	⁽¹⁾	251,070	D
Class A Common Stock	03/05/2026		A⁽³⁾		25,788	A	$0	25,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Units of Medline Holdings, LP	⁽⁴⁾	12/16/2025		A⁽¹⁾		251,070		⁽⁴⁾	⁽⁴⁾	Class A Common Stock	251,070	⁽¹⁾	251,070	I	See Footnote⁽⁴⁾
Incentive Units of Medline Holdings, LP	$15.42⁽⁵⁾⁽⁶⁾	12/16/2025		A⁽¹⁾		1,242,391		⁽⁵⁾⁽⁶⁾⁽⁷⁾	⁽⁵⁾⁽⁶⁾⁽⁷⁾	Class A Common Stock	1,242,391	⁽¹⁾	1,242,391	I	See Footnote⁽⁵⁾⁽⁶⁾
Incentive Units of Medline Holdings, LP	$15.23⁽⁵⁾⁽⁶⁾	12/16/2025		A⁽¹⁾		189,352		⁽⁵⁾⁽⁶⁾⁽⁸⁾	⁽⁵⁾⁽⁶⁾⁽⁸⁾	Class A Common Stock	189,352	⁽¹⁾	189,352	I	See Footnote⁽⁵⁾⁽⁶⁾
Incentive Units of Medline Holdings, LP	$19.01⁽⁵⁾⁽⁶⁾	12/16/2025		A⁽¹⁾		132,771		⁽⁵⁾⁽⁶⁾⁽⁹⁾	⁽⁵⁾⁽⁶⁾⁽⁹⁾	Class A Common Stock	132,771	⁽¹⁾	132,771	I	See Footnote⁽⁵⁾⁽⁶⁾
Incentive Units of Medline Holdings, LP	$27.68⁽⁵⁾⁽⁶⁾	12/16/2025		A⁽¹⁾		220,813		⁽⁵⁾⁽⁶⁾⁽¹⁰⁾	⁽⁵⁾⁽⁶⁾⁽¹⁰⁾	Class A Common Stock	220,813	⁽¹⁾	220,813	I	See Footnote⁽⁵⁾⁽⁶⁾

Explanation of Responses:

1. These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.

2. Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each common unit of Medline Holdings, LP ("Common Units") held. Upon an exchange of Common Units for shares of the Issuer's Class A common stock ("Class A Common Stock"), an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled.

3. Represents a grant of restricted stock units ("RSUs"), of which 25% vest on June 15, 2026 and the remaining 75% vest in three equal annual installments beginning on March 1, 2027.

4. Pursuant to the terms of an exchange agreement, dated as of December 16, 2025 (the "Exchange Agreement"), holders have the right to exchange their Common Units for shares of the Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units are held indirectly through Medline Management Aggregator LLC.

5. Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.

6. (Continued from Footnote 5 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.

7. 80% of these Incentive Units have vested, and the remaining 20% vest on October 21, 2026.

8. 40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on April 1, 2026.

9. 20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on March 29, 2026.

10. These Incentive Units vest in five equal annual installments beginning on March 28, 2026.

	/s/ Nicole Fritz, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity award did Medline (MDLN) CPO Amanda Laabs receive on March 5, 2026?

Amanda Laabs received a grant of 25,788 restricted stock units of Medline Class A common stock at $0.00 per share. These RSUs vest 25% on June 15, 2026 and the remaining 75% in three equal annual installments beginning March 1, 2027.

How do Medline Holdings, LP Common Units relate to Medline (MDLN) Class A shares?

Holders of Medline Holdings, LP Common Units may exchange them for Medline Class A common stock on a one‑for‑one basis under an exchange agreement. The exchange ratio can be adjusted for stock splits, stock dividends, and reclassifications, and the exchange rights do not expire.

What is the role of Medline Class B common stock in this Form 4 for MDLN?

Class B common stock has no economic value and carries one vote per share. One Class B share is issued for each Common Unit held, and an equivalent number of Class B shares is automatically cancelled when those Common Units are exchanged for Class A common stock.

What Incentive Units of Medline Holdings, LP were reported in this MDLN Form 4?

The filing reports several grants of Incentive Units of Medline Holdings, LP, which are profit interests similar to stock appreciation rights. Vested Incentive Units can be converted into Common Units based on formulas referencing a per unit participation threshold and the public trading price of Class A common stock.

How are the Medline (MDLN) Incentive Units held and can they expire?

The Incentive Units are held indirectly through Medline Management Aggregator LLC and have no expiration date. Once vested, they may be converted into Common Units, which are then exchangeable on a one‑for‑one basis for Medline Class A common stock under the exchange agreement.

What vesting schedules apply to the Incentive Units reported for Medline (MDLN)?

The filing notes multiple vesting schedules: one block is 80% vested with the remaining 20% vesting on October 21, 2026; others vest 60% or 80% over three to five equal annual installments beginning on dates in 2026, including April 1, March 29, and March 28.